San Francisco, June 06, 2025 - 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, has announced the approval of non-qualified stock options for three new employees. This decision, made by the Compensation Committee of the Company's Board of Directors, involves the issuance of options to purchase a total of 61,100 shares of 89bio's common stock. These inducement grants, effective June 3, 2025, are part of the 2023 Inducement Plan and align with Nasdaq Listing Rule 5635(c)(4). The exercise price for these options corresponds to the closing price on the grant date, and the options will vest over four years, with 25% vesting at the end of the first year and the remainder vesting quarterly, contingent upon continued employment.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。